Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

66.7%

4 terminated/withdrawn out of 6 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05771896Phase 3Withdrawn

Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC

Role: lead

NCT04917640Withdrawn

Registry for Accelerated Partial Breast Irradiation With (SBRT) or (IMRT)

Role: lead

NCT04681456Terminated

Skin Cancer Oncology Radiation Evidence Registry

Role: lead

NCT02381405Not ApplicableTerminated

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®)- for Maintaining Bowel Regularity in Patients With GI Toxicity From Any Combination of Therapy Including Tyrosine Kinase Inhibitors (TKI)

Role: lead

NCT02339948Not ApplicableCompleted

Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma

Role: lead

NCT02232230Completed

A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

Role: lead

All 6 trials loaded